Keywords: debio, boosts, peg-ifn, efficacy, ph, iia, study
Debio 025 boosts Peg-IFN efficacy in Ph IIa study
Article | 05 May 2008
Lausanne, Switzerland-based drug developer Debiopharm presented positive efficacy results from a Phase IIa study with Debio 025, a selective cyclophilin inhibitor. ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
